DUBLIN–(BUSINESS WIRE)–The “Urothelial Carcinoma – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “Urothelial Carcinoma- Pipeline Insight, 2022” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Urothelial Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Urothelial Carcinoma pipeline landscape is provided which includes the disease overview and Urothelial Carcinoma treatment guidelines.
The assessment part of the report embraces, in depth Urothelial Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Urothelial Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Urothelial Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.
Urothelial Carcinoma Emerging Drugs Chapters
This segment of the Urothelial Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Urothelial Carcinoma Emerging Drugs
Disitamab vedotin – Yantai Rongchang Pharmaceutical
Disitamab vedotin is a novel ADC that selectively delivers the anti-cancer agent monomethyl auristatin E (MMAE) into HER2-expressing tumor cells. The novel antibody component of the ADC exhibits a higher affinity and increased internalization rate as compared to trastuzumab in preclinical models, and in animal models, demonstrates promising antitumor activity. It is the first domestically developed ADC in China to receive marketing approval. In June 2021, disitamab vedotin received conditional approval by the NMPA of China to treat locally advanced or metastatic gastric cancer (GEJ carcinoma). In July 2021, the NMPA accepted the New Drug Application for disitamab vedotin in locally advanced or metastatic urothelial carcinoma. In addition, disitamab vedotin has shown significant antitumor activity in clinical trials of a number of HER2-expressing cancers, including those with low HER2 expression. It is currently being studied in multiple late-stage clinical trials across several solid tumor types.
Vactosertib : MedPacto
Vactosertib is an Oral, potent and selective TGFBRI (ALK5) inhibitor, promotes the cancer cell killing activity of immune cells and inhibits the proliferation of cancer stem cells, angiogenesis and metastasis. In addition, vactosertib can support various cancer treatments to attack cancer cells by suppressing stroma formation. Currently, combination trials with various anti-cancer treatments such as immunotherapy, targeted therapy and chemotherapy are underway.
Infigratinib : QED Therapeutics
QED Therapeutics’ lead investigational candidate is infigratinib (BGJ398), an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity that is believed to be meaningful in clinical measures such as overall response rate in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia.
Urothelial Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Urothelial Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Urothelial Carcinoma
There are approx. 50+ key companies which are developing the therapies for Urothelial Carcinoma. The companies which have their Urothelial Carcinoma drug candidates in the most advanced stage, i.e. Pre-Registration include, Yantai Rongchang Pharmaceutical.
Key Players
- Yantai Rongchang Pharmaceutical
- RemeGen
- MedPacto
- QED Therapeutics
- Novartis
- Sorrento Therapeutics
- Lee’s Pharmaceutical
- Merck KGaA
Key Products
- Disitamab vedotin
- Vactosertib
- Infigratinib
- Socazolimab
- Avelumab
- Rogaratinib
- AZD4547
- MRx0518
Key Topics Covered:
Introduction
Executive Summary
Urothelial Carcinoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Urothelial Carcinoma- Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Omalizumab: Genentech, Inc.
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Dupilumab: Regeneron
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
INP20: InnoUp Farma
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
INI2004: Inimmune
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Urothelial Carcinoma Key Companies
Urothelial Carcinoma Key Products
Urothelial Carcinoma- Unmet Needs
Urothelial Carcinoma- Market Drivers and Barriers
Urothelial Carcinoma- Future Perspectives and Conclusion
Urothelial Carcinoma Analyst Views
Urothelial Carcinoma Key Companies
Appendix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/phqy39
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
